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Systemic Lupus Erythematosus Review
Brian L. Kotzin Studies using several animal models have contributed
greatly to the elucidation of SLE pathogenesis (reviewedDepartments of Medicine and Pediatrics
National Jewish Center for Immunology by Theofilopoulos and Dixon, 1985; Cohen and Eisen-
berg, 1991). Examples include the F1 hybrid of Newand Respiratory Medicine
1400 Jackson Street Zealand black (NZB) and New Zealand white (NZW)
mice, MRL mice homozygous for the lymphoprolifera-Denver, Colorado 80206
Departments of Medicine and Immunology tion (lpr) gene (MRL-lpr/lpr), and BXSB mice, which carry
the disease-accelerating Yaa gene on the Y chromo-University of Colorado Health Sciences Center
Denver, Colorado 80262 some. These different strains are primarily models of
lupus-like glomerulonephritis associated with the pro-
Systemic lupus erythematosus (SLE) is considered to duction of IgG antibodies to DNA.
be the prototypic systemic autoimmune disease. In con-
trast to autoimmune diseases such as multiple sclerosis
and type 1 diabetes mellitus, SLE has the potential to Autoantibody Production and
involve multiple organ systems directly, and its clinical Disease Manifestations
manifestations are extremely diverse and variable (re- Among the myriad of autoantibodies produced in SLE,
viewed by Kotzin and O'Dell, 1995). For example, some principal targets include certain protein±nucleic acid
patients may demonstrate predominantly skin rash and complexes, notably chromatin, the U1 and Sm small
joint pain, show spontaneous remissions, and require nuclear ribonucleoprotein (snRNP) particles,and theRo/
little medication. The other end of the spectrum includes SSA and La/SSB RNP complexes (reviewed by Tan,
patients who demonstrate severe and progressive kid- 1989; Kotzin and O'Dell, 1995). The multivalent nature
ney involvement (glomerulonephritis) that requires ther- of these complexes and their ability to cross-link B cell
apy with high doses of steroidsand cytotoxic drugssuch receptors as well as their concentration on apoptotic
as cyclophosphamide. Criteria for the classification of cells have been proposed as explanations for their pre-
SLE have been established to facilitate the uniform re- ferential immunogenicity (Casciola-Rosen et al., 1994).
porting of SLE cases in studies. However, a multitude Autoantibodies to phospholipids (complexed to b2 gly-
of different phenotypes are encompassed within this coprotein 1) are also relatively frequent and associated
classification, and it remains unclear whether SLE repre- with thrombotic complications, a major clinical problem
sents a single pathologic entity with variable expression in some patients. A separate group of autoantibodies
or a group of related conditions. This heterogeneity has in SLE are directed to cell surface molecules. These
greatly confounded studies of genetic associations and latter specificities are easiest to understand in terms
pathogenic mechanisms. of their immunopathology, causing problems such as
Although SLE can occur at nearly any age, women of hemolytic anemia and platelet destruction (thrombocy-
childbearing age are primarily affected. The female to topenia). The mechanism by which most autoantibodies
male ratio is greatest (>8:1) for patients presenting be- in lupus may cause disease remains unclear. There is
tween ages 15 to 50 years, whereas the ratio is closer little evidence that anti-nuclear antibodies can readily
to 2:1 for disease that develops during childhood or after penetrate cellular membranes and cause disease by
menopause. Incidence rates for patients and studies binding to their intracellular targets. However, these au-
in certain animal models support a role for estrogens toantibodies may form immune complexes as described
enhancing and androgens protecting against disease below for lupus nephritis, and a similar mechanism may
development. In the United States, the chance of a cau- be responsible for other disease manifestations such
casian female developing SLE in her lifetime is approxi- as arthritis, serositis, and vasculitis.
mately 1 in 700, and the incidence may be two to four IgG autoantibodies to double-stranded DNA appear
times greater for blacks and hispanics. The overall prev- to play a prominent role in the immune complex glomer-
alence of SLE (z1 in 2000) is about the same as multiple ulonephritis of SLE (reviewed by Kotzin and O'Dell,
sclerosis and about 5- to 10-fold less than type 1 diabe- 1995). Interestingly, anti-DNA antibodies do not appear
tes mellitus and rheumatoid arthritis. to mediate renal damage through the deposition of cir-
The common denominator among SLE patients is im- culating immune complexes, and two alternative theo-
munoglobulin G (IgG) autoantibody production, and the ries have been proposed to explain their pathogenic
hallmark of this disease is elevated serum levels of anti- mechanism. In the first, DNA initially binds to the glomer-
bodies to nuclear constituents (i.e., anti-nuclear anti- ulus and is then recognized by anti-DNA antibodies,
bodies). In contrast to the other autoimmune diseases leading to in situ complex formation (Bernstein et al.,
discussed in this review series, T cells do not appear 1995). In an alternative model, the subset of pathogenic
to play a direct role in tissue damage in SLE, although, anti-DNA antibodies is able to cross-react with glomeru-
as discussed below, T cells are clearly involved in the lar structures that are not DNA in origin. Although most
development of autoantibody production. Figure 1 pres- studies have focused only on anti-DNA antibodies in the
ents a conceptual framework for the pathogenesis of cause of lupus nephritis, considerable evidence indi-
SLE, and the major events in this model provide the cates that autoantibodies to non-DNA antigens are also
important. For example, in the (NZB 3 NZW)F1 model,basis for the discussion below.
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or Sm/U1RNP) have been targeted by the autoantibody
response.
Experiments with mice expressing transgenes encod-
ing self-reactive antibodies have demonstrated that B
cell development involves a process of tolerance that
deletes or functionally inactivates autoreactive cells, in-
cluding some specificities characteristic of SLE (re-
viewed by Goodnow et al., 1995; Chen et al., 1995).
However, it is important to note that provision of a pow-
erful CD4 T cell driving force is sufficient for lupus-like
IgG autoantibody production and disease to develop in
normal animals. This is observed, for example, in models
of chronic graft-versus-host disease in which the trans-
ferred T cells are alloreactive, and these studies indicate
that potentially pathologic B cells are part of the periph-
eral repertoire or rapidly develop during this T cell±
driven process. Thus, defects in central B cell tolerance
do not appear to be necessary to allow for lupus-like
autoantibody production.Furthermore, the ability of nor-
mal animals to generate autoantibody responses that
spread to multiple determinants on a particular nuclear
complex after immunization with one peptide or compo-
nent of this complex also supports this conclusion
(Bockenstedt et al., 1995; Topfer et al., 1995; James et
al., 1995).
CD4 T Cell Dependence of
Autoantibody Production
The association of SLE with particular class II major
histocompatibility complex (MHC) alleles and the affinity
maturation of IgG autoantibody production in this dis-
ease strongly suggest that CD4 T cells are important in
the pathogenesis of disease. Furthermore, in all of the
Figure 1. Hypothetical Scheme for Immunopathogenic Events in the major murine models, treatment with anti-CD4 antibod-
Development of SLE ies can ameliorate IgG autoantibody production and dis-
ease. Additional studies indicate that blocking T cell
activation or T cell±B cell interactions will also prevent
genetic studies have suggested a major pathogenic role autoantibody production and disease (Finck et al., 1994;
for autoantibodies to the endogenous retroviral glyco- Mohan et al., 1995). The specificities of the autoreactive
protein (gp70) and gp70±anti-gp70 immune complexes T cells, however, have not been well characterized, and
(Izui et al., 1981). the nature of T cell help in SLE may indeed differ from
conventional responses. In the anti-DNA response, it
seems unlikely that T cells directed to DNA determinants
B Cell Tolerance and Activation in Lupus are operative. Studies in murine lupus have shown that
Evidence strongly supports the conclusions that patho- a non-DNA nucleosomal antigen stimulates some auto-
genic IgG autoantibody production in SLE is selective reactive T cells that drive anti-DNA antibody±producing
for only certain self-antigens and that autoreactive B B cells (Mohan et al., 1993). Thus, a DNA-specific B cell
cells are driven by self-antigens. In SLE and lupus mice, could bind and internalize nucleosomes, with subse-
studies have repeatedly shown that a subset of anti- quent class II MHC presentation of histone or other
DNA antibody±producing B cells are clonally expanded chromosomalpeptides toT cells. In other studies, immu-
and that their immunoglobulin genes are modified by noglobulin peptides derived from an IgG anti-DNA auto-
somatic mutation (reviewed by Radic et al., 1993). This antibody were shown to stimulate T cells from (NZB 3
process mimics a normal T cell±dependent response NZW)F1 mice and enhance IgG anti-DNA antibody pro-
to foreign antigen, involving common mechanisms of duction (Singh et al., 1995).
somatic mutation, affinity maturation, and IgM to IgG In studies relevant to organ-specific autoimmune dis-
class switching. Studies have shown that anti-DNA anti- eases such as multiple sclerosis and type 1 diabetes
bodies in lupus preferentially utilize certain VH and VL mellitus, the evidence indicates that autoimmune and
genes. Analysis of their complementarity-determining potentially disease-causing T cells are present in the
normal peripheral T cell repertoire. Thus, these T cellsregions (CDRs), especially CDR3, have shown an in-
creased number of arginine residues that enhance the were not deleted during normal development in the thy-
mus, and their inactivity appears to be maintained bybinding of antibody to DNA and suggest selection by
DNA itself (Radic et al., 1993). That self-antigen is in- protective mechanisms of peripheral toleranceÐfunc-
tional inactivation, immunoregulation, and immunologi-volved in anti-nuclear antibody production in lupus is
further supported by studies showing that multiple epi- cal ignorance. The same scenario may exist for lupus-
relevant T cells despite the ubiquitous nature of thetopes on the same autoantigen particle (e.g., chromatin
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target autoantigens. Studies in lupus mice, for example, model and one phenotype is being considered, the ge-
have suggested that high affinity responses to self-anti- netic basis of lupus-like disease is remarkably complex,
gens are tolerized normally in the thymus (Herron et al., involving contributions from multiple genes in addition
1993). Other work has indicated that dominant determi- to class II MHC (Drake et al., 1995; Morel et al., 1994;
nants of a self-antigen that are processed and presented Kono et al., 1994). Furthermore, it seems likely that dif-
efficiently in the thymus will be effective tolerogens, but ferent genetic contributions are operative in different
T cells directed to cryptic self-determinants may escape animal models (and therefore in different patients), even
tolerance induction and be part of the normal peripheral when thesame phenotype is being followed. Some traits
T cell repertoire (reviewed by Sercarz et al., 1993). There- appear to be determined in a threshold manner (Morel
fore, abnormal presentation of such cryptic determi- et al., 1994; Drake et al., 1995). Thus, the particular
nants in the periphery or a defect in peripheral T cell combination of genes may be less important than just
tolerance in SLE could allow activation of autoimmune the accumulation of an adequate number of predispos-
T cells. Immunization of normal mice with cryptic pep- ing genes. An additional complexity relates to the fact
tides of a self-nuclear antigen has been shown to result that contributions are unlikely to represent genetic mu-
in lupus-like autoantibody production (Bockenstedt et tations rather than polymorphic alleles with subtle func-
al., 1995). tional differences. Related to this issue, in some analy-
Patternsof cytokineproduction by T cells appear to be ses of genes from lupus-prone strains, genes from the
critically important indiseases such as multiplesclerosis normal strain can be shown to have enhancing effects
and type 1 diabetes. These diseases appear to be de- on disease expression (Drake et al., 1995).
pendent on Th1-type responses, and deviation from this In addition to class II MHC genes, there is evidence
pattern may lead to protection from disease expression. that genetically determined complement deficiencies
In SLE, Th2-type responses may be important in disease also contribute to disease susceptibility in a subset of
development, as demonstrated in the chronic graft-ver- SLE patients. The mechanism for this influence is un-
sus-host model of disease. However, in spontaneous known. Some investigators have postulated defects in
murine models, the IgG isotypes most important for the clearance of infectious particles or immune com-
pathogenicity (IgG2a, IgG2b, and IgG3) suggest the ad- plexes, leading to enhanced autoantibody production.
ditional influence of Th1-type cytokines and the impor- Alternatively, complement gene defects may exemplify
tance of interferon-g. Although there is a wealth of data genetic influences that operate distal to autoantibody
regarding defects in cytokine production and immuno-
production, and similar genetic contributions appear to
regulatory T cells in SLE, it is not clear at this time be present in murine lupus nephritis. For example, these
whether any are primary to the pathologic process.
genetic contributions may allow enhanced deposition
or formation of immune complexes in the kidney or pos-
Environmental Triggers and Influences
sibly affect the inflammatory response or end-organ re-
Environmental influences on the expression of disease
sponse to complexes.
manifestations areclearly seen in SLE. These include the
A possible step forward in understanding genetic con-exacerbation of skin rash (or even systemic symptoms)
tributions in lupus relates to the identification of lpr andafter sun exposure, exacerbations of disease after viral
gld as mutations in Fas and Fas ligands, respectively,or bacterial infections, and changes in disease activity
which are involved in programmed cell death (apoptosis)after administration of exogenous hormones. It is also
(reviewed by Cohen and Eisenberg, 1991; van Houtenclear that chronic treatment of patients with certain
and Budd, 1994). Homozygosity for these mutations re-drugs (such as procainamide or hydralazine) can induce
sults in the acceleration of lupus-like autoimmunity asthe production of anti-nuclear antibodies and a lupus-
well as a massive accumulation of CD42 CD82 (doublelike disease (reviewed by Kotzin and O'Dell, 1995) and
negative) T cells. Full expression of lupus-like diseasethat intraperitoneal injection with pristane (2,6,10,14-
in MRL-lpr/lpr mice is dependent on contributions fromtetramethylpentadecane) can induce a lupus-like dis-
other non-MHC genes. Although the mechanism byease in normal mice (Satoh et al., 1995). Despite this
which mutations in Fas lead to accelerated autoimmu-information, there is no clear evidence that an environ-
nity is unknown, the strongest hypothesis is that self-mental trigger is involved in the initiation of human SLE.
reactive T and B cells arise when they fail to undergoThe fact that approximately 75% of monozygotic twins
apoptosis normally. Studies have shown that both Tare discordant for disease expression has also been
cells and B cells must carry the lpr mutation for maximalused as evidence to support the existence of an environ-
autoantibody production to occur. Fas may not be im-mental stimulus. However, mouse strains can also be
portant in intrathymic tolerance during T cell develop-created such that 25% reproducibly develop disease or
ment, and studies support the contention that peripheralproduce particular autoantibodies, and careful examina-
T cell tolerance mechanisms are primarily affected bytion of positive mice has excluded environmental effects
the lpr mutation (Herron et al., 1993; Singer and Abbas,as the major factor in variable expression (Eisenberg et
1994). Studies suggest that central B cell tolerance alsoal., 1987; Drake et al., 1995). In these mice, the probabil-
may be relatively independent of Fas, and surface ex-ity of disease appears to be totally genetically deter-
pression of Fas on B cells may be most important inmined, and unknown stochastic (random) events deter-
preventing inappropriate CD4 T cell±dependent expan-mine which will develop disease. Overall, the importance
sion of autoreactive B cells in the periphery (Goodnowof environmental triggers in human SLE remains unclear.
et al., 1995; Rathmell and Goodnow, 1994; Rathmell et
al., 1995; Rothstein et al., 1995). Fas mutations haveGenetic Contributions
been identified in a few childrenwith lymphoproliferativeMany aspects of the genetic basis of lupus are reviewed
in a separate paper in this series. Even when one animal syndromes and evidence of autoimmunity. However, it
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immune antibodies. J. Immunol. 150, 4966±4977.part to the lpr or gld phenotype in human SLE, and
Rathmell, J.C., and Goodnow, C.C. (1994). Effects of the lpr mutationrecent studies have not found defects of these genes
on elimination and inactivation of self-reactive B cells. J. Immunol.in SLE patients. Still, there is a belief that other genes
153, 2831±2842.
involved in apoptosis or related cell signaling pathways
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